These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27144973)

  • 1. A novel antagonist anti-cMet antibody with antitumor activities targeting both ligand-dependent and ligand-independent c-Met receptors.
    Gonzalez A; Broussas M; Beau-Larvor C; Haeuw JF; Boute N; Robert A; Champion T; Beck A; Bailly C; Corvaïa N; Goetsch L
    Int J Cancer; 2016 Oct; 139(8):1851-63. PubMed ID: 27144973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
    Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
    Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth.
    Liu L; Zeng W; Wortinger MA; Yan SB; Cornwell P; Peek VL; Stephens JR; Tetreault JW; Xia J; Manro JR; Credille KM; Ballard DW; Brown-Augsburger P; Wacheck V; Chow CK; Huang L; Wang Y; Denning I; Davies J; Tang Y; Vaillancourt P; Lu J
    Clin Cancer Res; 2014 Dec; 20(23):6059-70. PubMed ID: 25231402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621.
    Michaud NR; Jani JP; Hillerman S; Tsaparikos KE; Barbacci-Tobin EG; Knauth E; Putz H; Campbell M; Karam GA; Chrunyk B; Gebhard DF; Green LL; Xu JJ; Dunn MC; Coskran TM; Lapointe JM; Cohen BD; Coleman KG; Bedian V; Vincent P; Kajiji S; Steyn SJ; Borzillo GV; Los G
    MAbs; 2012; 4(6):710-23. PubMed ID: 23007574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical development of a humanized neutralizing antibody targeting HGF.
    Kim H; Hong SH; Kim JY; Kim IC; Park YW; Lee SJ; Song SW; Kim JJ; Park G; Kim TM; Kim YH; Park JB; Chung J; Kim IH
    Exp Mol Med; 2017 Mar; 49(3):e309. PubMed ID: 28336956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.
    Merchant M; Ma X; Maun HR; Zheng Z; Peng J; Romero M; Huang A; Yang NY; Nishimura M; Greve J; Santell L; Zhang YW; Su Y; Kaufman DW; Billeci KL; Mai E; Moffat B; Lim A; Duenas ET; Phillips HS; Xiang H; Young JC; Vande Woude GF; Dennis MS; Reilly DE; Schwall RH; Starovasnik MA; Lazarus RA; Yansura DG
    Proc Natl Acad Sci U S A; 2013 Aug; 110(32):E2987-96. PubMed ID: 23882082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts.
    Yu Y; Chen Y; Ding G; Wang M; Wu H; Xu L; Rui X; Zhang Z
    Biochem Biophys Res Commun; 2015 Aug; 464(1):154-60. PubMed ID: 26093299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.
    Wang J; Goetsch L; Tucker L; Zhang Q; Gonzalez A; Vaidya KS; Oleksijew A; Boghaert E; Song M; Sokolova I; Pestova E; Anderson M; Pappano WN; Ansell P; Bhathena A; Naumovski L; Corvaia N; Reilly EB
    BMC Cancer; 2016 Feb; 16():105. PubMed ID: 26879245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
    Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity.
    Olwill SA; Joffroy C; Gille H; Vigna E; Matschiner G; Allersdorfer A; Lunde BM; Jaworski J; Burrows JF; Chiriaco C; Christian HJ; Hülsmeyer M; Trentmann S; Jensen K; Hohlbaum AM; Audoly L
    Mol Cancer Ther; 2013 Nov; 12(11):2459-71. PubMed ID: 24002935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-"decoy" strategy.
    Basilico C; Modica C; Maione F; Vigna E; Comoglio PM
    Int J Cancer; 2018 Oct; 143(7):1774-1785. PubMed ID: 29693242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts.
    Kim KJ; Wang L; Su YC; Gillespie GY; Salhotra A; Lal B; Laterra J
    Clin Cancer Res; 2006 Feb; 12(4):1292-8. PubMed ID: 16489086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling.
    Hultberg A; Morello V; Huyghe L; De Jonge N; Blanchetot C; Hanssens V; De Boeck G; Silence K; Festjens E; Heukers R; Roux B; Lamballe F; Ginestier C; Charafe-Jauffret E; Maina F; Brouckaert P; Saunders M; Thibault A; Dreier T; de Haard H; Michieli P
    Cancer Res; 2015 Aug; 75(16):3373-83. PubMed ID: 26141862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma.
    Gao CF; Xie Q; Zhang YW; Su Y; Zhao P; Cao B; Furge K; Sun J; Rex K; Osgood T; Coxon A; Burgess TL; Vande Woude GF
    Mol Cancer Ther; 2009 Oct; 8(10):2803-10. PubMed ID: 19825800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A receptor-antibody hybrid hampering MET-driven metastatic spread.
    Modica C; Basilico C; Chiriaco C; Borrelli N; Comoglio PM; Vigna E
    J Exp Clin Cancer Res; 2021 Jan; 40(1):32. PubMed ID: 33446252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain.
    Park H; Kim D; Kim E; Sa JK; Lee HW; Yu S; Oh J; Kim SH; Yoon Y; Nam DH
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28902178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sym015: A Highly Efficacious Antibody Mixture against
    Poulsen TT; Grandal MM; Skartved NJØ; Hald R; Alifrangis L; Koefoed K; Lindsted T; Fröhlich C; Pollmann SE; Eriksen KW; Dahlman A; Jacobsen HJ; Bouquin T; Pedersen MW; Horak ID; Lantto J; Kragh M
    Clin Cancer Res; 2017 Oct; 23(19):5923-5935. PubMed ID: 28679766
    [No Abstract]   [Full Text] [Related]  

  • 18. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma.
    Davis IJ; McFadden AW; Zhang Y; Coxon A; Burgess TL; Wagner AJ; Fisher DE
    Cancer Res; 2010 Jan; 70(2):639-45. PubMed ID: 20068147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy.
    Godar M; Morello V; Sadi A; Hultberg A; De Jonge N; Basilico C; Hanssens V; Saunders M; Lambrecht BN; El Khattabi M; de Haard H; Michieli P; Blanchetot C
    Sci Rep; 2016 Aug; 6():31621. PubMed ID: 27546726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel xenograft model expressing human hepatocyte growth factor shows ligand-dependent growth of c-Met-expressing tumors.
    Francone TD; Landmann RG; Chen CT; Sun MY; Kuntz EJ; Zeng Z; Dematteo RP; Paty PB; Weiser MR
    Mol Cancer Ther; 2007 Apr; 6(4):1460-6. PubMed ID: 17431125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.